Validated using a knockout cell line
Recombinant
RabMAb

Anti-CPT2 antibody [EPR13626] - C-terminal (ab181114)

Overview

  • Product name
    Anti-CPT2 antibody [EPR13626] - C-terminal
    See all CPT2 primary antibodies
  • Description
    Rabbit monoclonal [EPR13626] to CPT2 - C-terminal
  • Host species
    Rabbit
  • Tested applications
    Suitable for: IHC-P, WB, ICC/IFmore details
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    Synthetic peptide (the amino acid sequence is considered to be commercially sensitive) within Human CPT2 aa 600 to the C-terminus. The exact sequence is proprietary.
    Database link: P23786

  • Positive control
    • Human fetal liver and fetal kidney lysates; Human liver and skeletal muscle tissues; MCF7 cells, Rat kidney and liver lysates, Mouse heart and kidney lysates, Mouse kidney tissue and Rat colon tissue.
  • General notes

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents

    We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.

    This product is a recombinant rabbit monoclonal antibody.

Properties

Applications

Our Abpromise guarantee covers the use of ab181114 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P 1/50 - 1/100.

See IHC antigen retrieval protocols.

WB 1/1000 - 1/10000. Detects a band of approximately 67 kDa (predicted molecular weight: 74 kDa).
ICC/IF 1/50 - 1/100.

Target

  • Pathway
    Lipid metabolism; fatty acid beta-oxidation.
  • Involvement in disease
    Defects in CPT2 are the cause of carnitine palmitoyltransferase 2 deficiency (CPT2D) [MIM:255110, 600649]; also known as CPT-II deficiency or CPT2 deficiency. CPT2D is an autosomal recessive disorder characterized by recurrent myoglobinuria, episodes of muscle pain, stiffness, and rhabdomyolysis. These symptoms are triggered by prolonged exercise, fasting or viral infection and patients are usually young adults. In addition to this classical, late-onset, muscular type, a hepatic or hepatocardiomuscular form has been reported in infants. Clinical pictures in these children or neonates include hypoketotic hypoglycemia, liver dysfunction, cardiomyopathy and sudden death.
    Defects in CPT2 are the cause of carnitine palmitoyltransferase 2 deficiency, lethal neonatal (CPT2D-LN) [MIM:608836]; also known as lethal neonatal CPT-II deficiency. It is a lethal neonatal form of CPT2D. This rarely presentation is antenatal with cerebral periventricular cysts and cystic dysplastic kidneys. The clinical variability of the disease is likely attributed to the variable residual enzymatic activity.
  • Sequence similarities
    Belongs to the carnitine/choline acetyltransferase family.
  • Cellular localization
    Mitochondrion inner membrane.
  • Information by UniProt
  • Database links
  • Alternative names
    • Carnitine O palmitoyltransferase 2 antibody
    • Carnitine O palmitoyltransferase 2 mitochondrial antibody
    • Carnitine O-palmitoyltransferase 2 antibody
    • Carnitine palmitoyltransferase 2 antibody
    • Carnitine palmitoyltransferase II antibody
    • CPT 1 antibody
    • CPT 2 antibody
    • CPT II antibody
    • CPT1 antibody
    • CPT2 antibody
    • CPT2_HUMAN antibody
    • CPTASE antibody
    • CPTII antibody
    • IIAE4 antibody
    • mitochondrial antibody
    see all

Images

  • Lane 1: Wild-type HAP1 whole cell lysate (20 µg)
    Lane 2: CPT2 knockout HAP1 whole cell lysate (20 µg)
    Lane 3: HeLa whole cell lysate (20 µg)
    Lane 4: MCF7 whole cell lysate (20 µg)

    Lanes 1 - 4: Merged signal (red and green). Green - ab181114 observed at 70 kDa. Red - loading control, ab8245, observed at 37 kDa.

    ab181114 was shown to specifically react with CPT2 in wild-type HAP1 cells. No band was observed when CPT2 knockout samples were examined. Wild-type and CPT2 knockout samples were subjected to SDS-PAGE.  Ab181114 and ab8245 (Mouse anti GAPDH loading control) were incubated overnight at 4°C at 1/1000 dilution and 1/10,000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed ab216773 and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed ab216776 secondary antibodies at 1/10,000 dilution for 1 hour at room temperature before imaging.

  • Immunocytochemistry/Immunofluorescence analysis of MCF-7 (human breast carcinoma) cells labelling CPT2 with purified ab181114 at 1/100. Cells were fixed with 100% methanol and permeabilized with 0.1% Triton X-100. ab150077, Alexa Fluor® 488-conjugated goat anti-rabbit IgG (1/1000) was used as the secondary antibody. The cells were co-stained with ab7291, a mouse anti-tubulin antibody (1/1000) using ab150120, an Alexa Fluor® 594-conjugated goat anti-mouse IgG (1/1000) as the secondary. Nuclei couterstained with DAPI (blue).

    For negative control 1, rabbit primary antibody was used, followed by anti-mouse secondary antibody (ab150120). For negative control 2, mouse primary antibody (ab7291) was used followed by anti-rabbit secondary antibody (ab150077).  

  • All lanes : Anti-CPT2 antibody [EPR13626] - C-terminal (ab181114) at 1/2000 dilution (purified)

    Lane 1 : Human fetal kidney tissue lysate
    Lane 2 : MCF-7 (human breast carcinoma) whole cell lysate
    Lane 3 : Mouse heart tissue lysate
    Lane 4 : Mouse kidney tissue lysate

    Lysates/proteins at 20 µg per lane.

    Secondary
    All lanes : Anti-Rabbit IgG (HRP), specific to the non-reduced form of IgG at 1/2000 dilution

    Predicted band size: 74 kDa
    Observed band size: 67 kDa (why is the actual band size different from the predicted?)



    Blocking and diluting buffer 5% NFDM/TBST
  • All lanes : Anti-CPT2 antibody [EPR13626] - C-terminal (ab181114) at 1/1000 dilution (purified)

    Lane 1 : Rat kidney tissue lysate
    Lane 2 : Rat liver tissue lysate

    Lysates/proteins at 20 µg per lane.

    Secondary
    All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution

    Predicted band size: 74 kDa



    Blocking and diluting buffer 5% NFDM/TBST
  • All lanes : Anti-CPT2 antibody [EPR13626] - C-terminal (ab181114) at 1/10000 dilution (unpurified)

    Lane 1 : Human fetal liver tissue lysate
    Lane 2 : Human fetal kidney tissue lysate

    Lysates/proteins at 20 µg per lane.

    Secondary
    All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab136636) at 1/500 dilution

    Predicted band size: 74 kDa
    Observed band size: 67 kDa (why is the actual band size different from the predicted?)

  • Immunohistochemical analysis of paraffin embedded rat colon tissue section labelling CPT2 with purified ab181114 at dilution of 1/50. The secondary antibody used was HRP-conjugated Goat Anti-Rabbit IgG H&L (ab97051) at dilution of 1/500. The sample was counter-stained with hematoxylin. Antigen retrieval was perfomed using Tris-EDTA buffer, pH 9.0. PBS was used instead of the primary antibody as the negative control and is shown in the inset. 

  • Immunohistochemical analysis of paraffin embedded mouse kidney tissue section labelling CPT2 with purified ab181114 at dilution of 1/50. The secondary antibody used was HRP-conjugated Goat Anti-Rabbit IgG H&L (ab97051) at dilution of 1/500. The sample was counter-stained with hematoxylin. Antigen retrieval was perfomed using Tris-EDTA buffer, pH 9.0. PBS was used instead of the primary antibody as the negative control and is shown in the inset. 

  • Immunohistochemical analysis of paraffin embedded human liver carcinoma tissue section labelling CPT2 with purified ab181114 at dilution of 1/50. The secondary antibody used was Goat Anti-Rabbit IgG H&L (HRP) (ab97051), at a dilution of 1/500. The sample was counter-stained with hematoxylin. Antigen retrieval was perfomed using Tris-EDTA buffer, pH 9.0. PBS was used instead of the primary antibody as the negative control and is shown in the inset. 

  • Immunohistochemical analysis of paraffin-embedded Human liver tissue labeling CPT2 with unpurified ab181114 at 1/100 dilution, followed by prediluted HRP Polymer for Rabbit IgG. Counter stained with Hematoxylin.

  • Immunohistochemical analysis of paraffin-embedded Human skeletal muscle tissue labeling CPT2 with unpurified ab181114 at 1/100 dilution, followed by prediluted HRP Polymer for Rabbit IgG. Counter stained with Hematoxylin.

  • Immunofluorescent analysis of 4% paraformaldehyde-fixed MCF7 cells labeling CPT2 with unpurified ab181114 at 1/100 dilution, followed by Goat anti rabbit IgG (Alexa Fluor® 488) secondary antibody at 1/200 dilution. Counter stained with Dapi.

References

This product has been referenced in:
  • Schatton D  et al. CLUH regulates mitochondrial metabolism by controlling translation and decay of target mRNAs. J Cell Biol 216:675-693 (2017). WB ; Mouse . Read more (PubMed: 28188211) »
  • Gu JJ  et al. Mitochondrial carnitine palmitoyl transferase-II inactivity aggravates lipid accumulation in rat hepatocarcinogenesis. World J Gastroenterol 23:256-264 (2017). Read more (PubMed: 28127199) »

See all 3 Publications for this product

Customer reviews and Q&As

Application
Immunohistochemistry (Frozen sections)
Blocking step
Serum as blocking agent for 2 hour(s) and 0 minute(s) · Concentration: 10%
Sample
Rat Tissue sections (Brain-Hippocampus)
Specification
Brain-Hippocampus
Permeabilization
Yes - .1%TX-100
Fixative
Paraformaldehyde
Username

Abcam user community

Verified customer

Submitted Mar 24 2015

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up